Objective To describe the phenomenon of tau-negative amnestic dementia mimicking Alzheimer disease (AD) clinically and radiologically and to highlight the importance of biomarkers in AD research.
The availability first of amyloid PET imaging and now of tau PET imaging has fundamentally changed our approach to the antemortem diagnosis of dementia due to Alzheimer disease (AD). 1, 2 While it has long been known from neuropathologic studies that the clinical diagnosis of what was previously called probable AD in the 1984 criteria was only about 80% sensitive and specific at best, the neuropathologic basis of amnestic mild cognitive impairment (MCI) shows an even weaker relationship to neuropathologic AD. 3 Recent studies using amyloid PET imaging revealed similar inaccuracies in the clinical diagnoses of MCI or AD dementia. 4, 5 With the availability of tau PET, further experience has been gained in the clinicalbiomarker associations with pathophysiologic AD that will also lead to more refined diagnoses of what is and is not AD. 1, 6 Recently, the A/T/N biomarker classification scheme was proposed, 7 allowing independent classification of amyloid, tau, and neurodegeneration status. Patients who are A+ are thought to be on the AD pathway, with A− participants either being normal (A−/T−/N−) or harboring some non-AD pathology (A−/T−/ N+, A−/T+/N+, A−/T+/N−). 1 Crucially, however, amyloid positivity does not imply that neurodegeneration is due to AD: T−/N+ cases likely have another pathology driving their degeneration regardless of amyloid status. 1 With the recent addition of tau PET, this group can be identified and studied more readily. 2 If A+/T−/N+ participants can mimic AD clinically, this group may inadvertently be included in AD trials, with serious implications. Here, we report 8 T−/N+ cases that were clinically diagnosed with AD dementia or amnestic MCI (aMCI) due to AD.
Methods

Clinical assessment
All 8 participants were evaluated in the Mayo Clinic Alzheimer's Disease Research Center. A consensus diagnosis was given at a multidisciplinary meeting based on established criteria. 8 All participants completed a comprehensive neuropsychological battery as part of the Uniform Data Set designed by the National Alzheimer's Coordinating Center. Test scores were then converted to z scores controlling for age, sex, and education (https://www.alz.washington.edu/WEB/npsych_means.html). Because conversion is not available for the Rey-Osteroth Complex Figure, the raw score was converted to a standard score based on Mayo's Older Americans Normative Studies.
Standard protocol approvals, registrations, and patient consents The Mayo Clinic Institutional Review Board reviewed and approved this study. Written informed consent was obtained from all participants or their guardians.
Imaging protocol
Details of PET imaging and analysis have been described elsewhere. 1 Briefly, Pittsburgh compound B was used for amyloid PET, and flortaucipir (AV-1451) was used for tau PET. An amyloid standardized uptake value ratio (SUVR) was derived from the voxel-weighted median uptake in the prefrontal, orbitofrontal, parietal, temporal, anterior and posterior cingulate, and precuneus regions of interest. 1 The tau SUVR was based on the voxel-weighted median uptake in the entorhinal, amygdala, parahippocampal, fusiform, inferior temporal, and middle temporal regions of interest.
1 MRI was performed on 1 of 3 compatible 3T GE systems (GE Healthcare, Chicago, IL), and the AD-signature thickness (AD-sig) and hippocampal volume adjusted for intracranial volume were calculated. Previously established cut points were used. 1 
Results
Clinical findings
All participants were thought to have AD as the primary driver of their symptoms before any PET imaging and met the criteria for AD dementia (patients 1, 2, 5-8) or aMCI (patients 3 and 4). Neuropsychological results are summarized in the table. Both participants 1 and 2 had experienced several years of progressive short-term memory (STM) loss before presenting for evaluation, by which time some language impairment was evident in participant 2. Participants 3 and 4 had STM loss, corroborated by informants, but with minimal impairment of their activities of daily living. Participant 5 had an initial course of ≈6 years of progressive STM loss before other cognitive domains became affected. Participant 6 passed through a phase of aMCI before being diagnosed with dementia at the last visit. Participant 7 presented with STM loss for a few years before developing more general cognitive impairment by the time of initial assessment. Finally, participant 8 presented with STM loss, which remained the main cause of impairment in activities of daily living throughout follow-up despite poor test scores for nonmemory domains.
Imaging findings
Imaging results are shown in the figure. A cognitively normal and biomarker-negative (A−/T−/N−) control and a participant with typical AD dementia (A+/T+/N+) are shown for reference. All participants had hippocampal atrophy (hippocampal volume adjusted for intracranial volume <−1.15), and 3 participants fell below the AD-sig cutoff for elderly controls (2.57). Four participants were amyloid positive (SUVR >1.42), and all were tau negative (SUVR <1.33).
Glossary AD = Alzheimer disease; AD-sig = Alzheimer disease-signature thickness; aMCI = amnestic mild cognitive impairment; MCI = mild cognitive impairment; STM = short-term memory; SUVR = standardized uptake value ratio. 
Discussion
The participants presented here were clinically impaired with structural imaging evidence of neurodegeneration in the absence of any significant tau accumulation. Therefore, AD is unlikely to be a cause of their clinical presentation and neurodegenerative imaging findings. This highlights several important points about AD and the clinical and imaging metrics used to diagnose it. The lack of specificity of clinical AD criteria is evident, consistent with the fact that a significant proportion of cases with clinically suspected AD dementia lack AD pathology or biomarker evidence for AD, while a large proportion of clinically normal individuals have AD pathology or biomarker evidence supporting AD. Our findings plus prior reports have made it highly likely that many participants enrolled in AD dementia trials over the last few decades may not have had AD pathophysiology driving their clinical syndrome. 4, 5, 9 In addition, the presence of hippocampal atrophy in all participants and volume loss in other characteristic AD cortical areas in some emphasize the limitations of structural imaging, a problem of etiologic nonspecificity that increases with age as a greater proportion of cognitively normal participants fall below cutoff values. 9 However, the 4 participants who were amyloid positive emphasize the need for biomarker models that incorporate both amyloid and tau. 6 With the ATN model, the 8 participants would correctly be labeled as A−/T−/N+ (participants 1-3 and 6) or A+/T−/ N+ (participants 2, 5, 7 and 8), 2 patterns that are inconsistent with current models of pure AD given the absence of tau in the setting of neurodegeneration. 1, 7 We have previously postulated that neurodegeneration in the A−/T−/N+ group is the result of a heterogeneous group of non-AD pathologies that increase in prevalence with age such as hippocampal sclerosis, argyrophilic grain disease, and cerebrovascular disease. 9 Similarly, for the group of A+/T−/N+ participants, we suspect that a non-AD process is driving the neurodegeneration, with amyloidosis representing an early and asymptomatic phase of AD. Among cognitively normal participants, the prevalence of the A−/T−/N+ and A+/T−/N+ groups increases above the age of 75 years and peaks at ≈18% to 22% and 17% to 18%, respectively. 9 From the data presented here and other data from our center, we estimate that ≈27.5% of aMCI or dementia thought to be due to AD in those >75 years of age might be tau-PET negative, with half of these being amyloid-PET negative (appendix e-1, http:// links.lww.com/WNL/A239). This is consistent with prior reports that ≈50% of aMCI in the >80-year-old cohort is caused by non-AD pathologies, most notably hippocampal sclerosis and argyrophilic grain disease. 3 The age and the focal medial temporal and hippocampal atrophy in our participants would be consistent with hippocampal sclerosis, 3 ,10 a suspicion that was recently confirmed in 1 participant (participant 2) who had TDP-43-positive hippocampal sclerosis at autopsy and minimal evidence for AD (appendix e-1).
A notable limitation of our study is the fact that biomarker status was assessed with PET only, which may lack sensitivity to low Thal and Braak stages of the disease, so early AD may have been missed in our biomarker-negative cases. However, this would not account for their prominent amnesia and neurodegeneration, which would have to have an additional non-AD etiology. Similarly, the lack of pathologic confirmation can be seen as a weakness, but the delay between clinical presentation and pathologic examination complicates clinicpathologic correlations. We have compelling in vivo evidence that our participants lacked significant tau deposition, which would have been suspected if their degeneration was due to AD, again implicating non-AD pathologies.
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